[Platelet Metabolism in Clopidogrel Resistant and Sensitive Patients With Ischemic Heart Disease]

I Yu Grinshtein1,2, A A Savchenko1,2, Yu I Grinshtein1,2

  • 1Prof. V.F. Vojno-Yasenetsky Krasnoyarsk State Medical University, Krasnoyarsk, Russia.

Kardiologiia
|March 15, 2017
PubMed

Insights

Platelet enzyme activity differs in patients with ischemic heart disease (IHD) after coronary artery bypass grafting (CABG), impacting clopidogrel sensitivity. Understanding these metabolic changes is key for IHD management.

Area of Science:

  • Biochemistry
  • Cardiology
  • Pharmacology

Background:

  • Ischemic heart disease (IHD) poses a significant cardiovascular risk.
  • Coronary artery bypass grafting (CABG) is a common intervention for IHD.
  • Platelet function and metabolism are crucial in cardiovascular disease and antiplatelet therapy response.

Purpose of the Study:

  • To investigate the relationship between platelet nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP) dependent dehydrogenases.
  • To assess how these enzyme activities correlate with clopidogrel sensitivity in IHD patients post-CABG.

Main Methods:

  • Studied 51 male IHD patients before and after CABG, with 35 healthy men as controls.
  • Measured platelet aggregation and activity of NAD/NADP dependent dehydrogenases using aggregometry and bioluminescent methods.
  • Classified patients as clopidogrel sensitive or resistant based on ADP-induced platelet aggregation inhibition.

Main Results:

  • Platelet metabolism in IHD patients showed reduced activity in anaerobic energetics, antioxidant systems, and lipid catabolism pathways.
  • Clopidogrel resistance was associated with low pentose phosphate cycle activity and reduced tricarboxylic acid cycle flow.
  • Clopidogrel-sensitive patients exhibited increased NADP-malate dehydrogenase activity, linked to lipid anabolism.

Conclusions:

  • Platelet metabolic profiles differ between clopidogrel-sensitive and resistant IHD patients post-CABG.
  • Enzyme activity related to NAD/NADP dependent dehydrogenases may influence clopidogrel response in IHD patients.
  • These findings highlight potential biomarkers for predicting antiplatelet therapy efficacy in cardiovascular patients.
Abstract

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
10.2K
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
4.3K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
76
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
465
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
508